About
Treatment of Conditions Caused by Deficiencies in WAS Protein Expression
XL Therapeutics is a biopharmaceutical company aiming to develop small molecule compounds to treat patients suffering from Wiskott-Aldrich syndrome (WAS) and X-linked thrombocytopenia, rare primary human immunodeficiencies caused by the absence or suboptimal function of the WAS protein (WASp), an adaptor protein expressed exclusively in hematopoietic cells and essential for normal hematopoietic cell function.
Identity
| Name | XL Therapeutics |
|---|---|
| Slug | xl-therapeutics |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoMmt05AKDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, May 2019 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Ness Ziona |
| HQ address | Ness Ziona, Israel |
Web & social
| https://www.linkedin.com/company/11321986 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesHealthcareProvidersPatientsLife SciencesPharmaceuticals
Business models
B2B
Tags
medical-technologiesvascularpatientshospitalspharmaceuticalstreatments
Funding
| Total raised | — |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}